These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8281722)

  • 1. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification.
    Bahru Y; Kesteven P; Alberti KG; Walker M
    Diabet Med; 1993 Nov; 10(9):802-6. PubMed ID: 8281722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis and diabetic retinopathy in NIDDM.
    Mansfield MW; Grant PJ
    Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
    Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
    Diabetes Res Clin Pract; 1994 Jan; 22(2-3):123-8. PubMed ID: 8200293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
    Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
    Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
    Grant PJ
    Diabetes Care; 1996 Jan; 19(1):64-6. PubMed ID: 8720537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
    Hirano T; Kashiwazaki K; Moritomo Y; Nagano S; Adachi M
    Diabetes Res Clin Pract; 1997 Apr; 36(1):11-8. PubMed ID: 9187410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
    Gough SC; Rice PJ; McCormack L; Chapman C; Grant PJ
    Diabet Med; 1993; 10(7):638-42. PubMed ID: 8403825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes.
    Jokl R; Laimins M; Klein RL; Lyons TJ; Lopes-Virella MF; Colwell JA
    Diabetes Care; 1994 Aug; 17(8):818-23. PubMed ID: 7956624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance as a major determinant of increased coronary heart disease risk in postmenopausal women with Type 2 diabetes mellitus.
    Stoney RM; O'Dea K; Herbert KE; Dragicevic G; Giles GG; Cumpston GN; Best JD
    Diabet Med; 2001 Jun; 18(6):476-82. PubMed ID: 11472467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.
    Jain SK; Nagi DK; Slavin BM; Lumb PJ; Yudkin JS
    Diabet Med; 1993; 10(1):27-32. PubMed ID: 8435984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.
    Jokl R; Klein RL; Lopes-Virella MF; Colwell JA
    Diabetes Care; 1995 Aug; 18(8):1150-5. PubMed ID: 7587850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.
    Belalcazar LM; Ballantyne CM; Lang W; Haffner SM; Rushing J; Schwenke DC; Pi-Sunyer FX; Tracy RP;
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1689-95. PubMed ID: 21512162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
    Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
    Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
    Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
    Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.